

B² --5. (twice amended) A pharmaceutical composition according to claim 3 comprising 10^4 to 10^{11} colony-forming units, *Lactobacillus plantarum* LB931. --

--7. (twice amended) An absorbent product comprising *Lactobacillus plantarum* strain LB931, said strain has been assigned accession number DSM11918.--

B³ --8. (twice amended) An absorbent product according to claim 7, comprising 10^4 to 10^{11} cfu, *Lactobacillus plantarum* LB931.--

--9. (twice amended) A pharmaceutical composition according to claim 5 wherein said pharmaceutically acceptable carrier is skimmed milk, or a lactobacillus growth medium in powder form. --

B⁴ --12. (amended) The pharmaceutical composition according to claim 3, wherein said *Lactobacillus plantarum* LB931 is in an amount of 10^5 to 10^9 cfu. --

B⁶ --15. (amended) A method of preparing a pharmaceutical composition for preventing and/or treating urogenital infections, comprising:

adding *Lactobacillus plantarum*, strain LB931, said strain has been assigned accession number DSM11918 to said pharmaceutical composition.--

B6 --16. (amended) The method according to claim 15, wherein said pharmaceutical composition prevents or inhibits the growth of enterobacteria.--

--18. (amended) The method according to claim 15, wherein said absorbent product prevents or treats the growth of enterobacteria.--

B7 --19. (amended) The method according to claim 18, wherein said absorbent product is selected from the group consisting of a diaper, sanitary napkin, panty guard, incontinence guard and feminine hygiene product.--

B8 --21. (amended) The method according to claim 20, wherein said *Lactobacillus plantarum* is administered to said patient via a pharmaceutical composition selected from the group consisting of ointments, creams, liquid solutions, suppositories, and capsules.--

B9 --23. (amended) The method according to claim 20, wherein said absorbent product prevents or treats the growth of enterobacteria.--